Thanks Google Image for diagram
About one in five cases of breast cancer are Her2 positive—meaning the tumors are high in protein. Great news! Not only for those with Her2, but for those with Hodgkin’s lymphoma.
The Food and Drug Administration has approved T-DM1. Usually women with Her2 breast cancer are given Herceptin, a monoclonal antibody that attaches to proteins on some cancer cells and slows or stops the growth of the cells. (http://www.cancer.gov/dictionary) along with a type of chemo. In the trials, the two drugs were attached to each other. The chemo remains inactive until the Herceptin carries it to the tumor. Side effects reported are temporary nausea, and some muscle cramps. T-DM1 is expected to be on market next year. http://www.utsandiego.com/news/2012/jun/20/tp-new-arsenal-in-cancer-war.